FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2487577029> ?p ?o ?g. }

• W2487577029 endingPage "235" @default.
• W2487577029 startingPage "227" @default.
• W2487577029 abstract "TAS-102 is a combination of the thymidine-based nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil. Efficacy and safety of TAS-102 in patients with metastatic colorectal cancer (mCRC) refractory or intolerant to standard therapies were evaluated in the phase 3 RECOURSE trial. Results of RECOURSE demonstrated significant improvement in overall survival (OS) and progression-free survival (PFS) with TAS-102 versus placebo [hazard ratio (HR) = 0.68 and 0.48 for OS and PFS, respectively; both P < 0.001]. The current analysis evaluates efficacy and safety of TAS-102 in the RECOURSE Spanish subgroup.Primary and key secondary endpoints were evaluated in a post hoc analysis of the RECOURSE Spanish subgroup, using univariate and multivariate analyses. Safety and tolerability were reported with descriptive statistics.The RECOURSE Spanish subgroup included 112 patients (mean age 61 years, 62 % male). Median OS was 6.8 months in the TAS-102 group (n = 80) versus 4.6 months in the placebo group (n = 32) [HR = 0.47; 95 % confidence interval (CI): 0.28-0.78; P = 0.0032). Median PFS was 2.0 months in the TAS-102 group and 1.7 months in the placebo group (HR = 0.47; 95 % CI: 0.30-0.74; P = 0.001). Eighty (100 %) TAS-102 versus 31 (96.9 %) placebo patients had adverse events (AEs). The most common drug-related ≥Grade 3 AE was neutropenia (40 % TAS-102 versus 0 % placebo). There was 1 (1.3 %) case of febrile neutropenia in the TAS-102 group versus none in the placebo group.In the RECOURSE Spanish subgroup, TAS-102 was associated with significantly improved OS and PFS versus placebo, consistent with the overall RECOURSE population. No new safety signals were identified. CLINICALTRIALS.NCT01607957." @default.
• W2487577029 created "2016-08-23" @default.
• W2487577029 creator A5000655348 @default.
• W2487577029 creator A5001074035 @default.
• W2487577029 creator A5003707413 @default.
• W2487577029 creator A5015190461 @default.
• W2487577029 creator A5017763783 @default.
• W2487577029 creator A5031976935 @default.
• W2487577029 creator A5048223620 @default.
• W2487577029 creator A5053880366 @default.
• W2487577029 creator A5061408616 @default.
• W2487577029 creator A5083244979 @default.
• W2487577029 creator A5091727687 @default.
• W2487577029 date "2016-07-21" @default.
• W2487577029 modified "2023-10-02" @default.
• W2487577029 title "Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial" @default.
• W2487577029 cites W1821802350 @default.
• W2487577029 cites W1974054076 @default.
• W2487577029 cites W2019607817 @default.
• W2487577029 cites W2021102443 @default.
• W2487577029 cites W2045370737 @default.
• W2487577029 cites W2054301472 @default.
• W2487577029 cites W2054664824 @default.
• W2487577029 cites W2092754976 @default.
• W2487577029 cites W2116258698 @default.
• W2487577029 cites W2125337286 @default.
• W2487577029 cites W2132611552 @default.
• W2487577029 cites W2141434947 @default.
• W2487577029 cites W2146404049 @default.
• W2487577029 cites W2151180605 @default.
• W2487577029 cites W2408162929 @default.
• W2487577029 cites W242040007 @default.
• W2487577029 cites W4231402414 @default.
• W2487577029 cites W4236891330 @default.
• W2487577029 doi "https://doi.org/10.1007/s12094-016-1528-7" @default.
• W2487577029 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5239803" @default.
• W2487577029 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27443414" @default.
• W2487577029 hasPublicationYear "2016" @default.
• W2487577029 type Work @default.
• W2487577029 sameAs 2487577029 @default.
• W2487577029 citedByCount "23" @default.
• W2487577029 countsByYear W24875770292017 @default.
• W2487577029 countsByYear W24875770292018 @default.
• W2487577029 countsByYear W24875770292019 @default.
• W2487577029 countsByYear W24875770292020 @default.
• W2487577029 countsByYear W24875770292021 @default.
• W2487577029 countsByYear W24875770292022 @default.
• W2487577029 countsByYear W24875770292023 @default.
• W2487577029 crossrefType "journal-article" @default.
• W2487577029 hasAuthorship W2487577029A5000655348 @default.
• W2487577029 hasAuthorship W2487577029A5001074035 @default.
• W2487577029 hasAuthorship W2487577029A5003707413 @default.
• W2487577029 hasAuthorship W2487577029A5015190461 @default.
• W2487577029 hasAuthorship W2487577029A5017763783 @default.
• W2487577029 hasAuthorship W2487577029A5031976935 @default.
• W2487577029 hasAuthorship W2487577029A5048223620 @default.
• W2487577029 hasAuthorship W2487577029A5053880366 @default.
• W2487577029 hasAuthorship W2487577029A5061408616 @default.
• W2487577029 hasAuthorship W2487577029A5083244979 @default.
• W2487577029 hasAuthorship W2487577029A5091727687 @default.
• W2487577029 hasBestOaLocation W24875770291 @default.
• W2487577029 hasConcept C121608353 @default.
• W2487577029 hasConcept C126322002 @default.
• W2487577029 hasConcept C141071460 @default.
• W2487577029 hasConcept C142724271 @default.
• W2487577029 hasConcept C143998085 @default.
• W2487577029 hasConcept C144301174 @default.
• W2487577029 hasConcept C187960798 @default.
• W2487577029 hasConcept C197934379 @default.
• W2487577029 hasConcept C204787440 @default.
• W2487577029 hasConcept C207103383 @default.
• W2487577029 hasConcept C27081682 @default.
• W2487577029 hasConcept C2776694085 @default.
• W2487577029 hasConcept C2777063308 @default.
• W2487577029 hasConcept C2778375690 @default.
• W2487577029 hasConcept C2778850193 @default.
• W2487577029 hasConcept C38180746 @default.
• W2487577029 hasConcept C44249647 @default.
• W2487577029 hasConcept C526805850 @default.
• W2487577029 hasConcept C71924100 @default.
• W2487577029 hasConcept C90924648 @default.
• W2487577029 hasConceptScore W2487577029C121608353 @default.
• W2487577029 hasConceptScore W2487577029C126322002 @default.
• W2487577029 hasConceptScore W2487577029C141071460 @default.
• W2487577029 hasConceptScore W2487577029C142724271 @default.
• W2487577029 hasConceptScore W2487577029C143998085 @default.
• W2487577029 hasConceptScore W2487577029C144301174 @default.
• W2487577029 hasConceptScore W2487577029C187960798 @default.
• W2487577029 hasConceptScore W2487577029C197934379 @default.
• W2487577029 hasConceptScore W2487577029C204787440 @default.
• W2487577029 hasConceptScore W2487577029C207103383 @default.
• W2487577029 hasConceptScore W2487577029C27081682 @default.
• W2487577029 hasConceptScore W2487577029C2776694085 @default.
• W2487577029 hasConceptScore W2487577029C2777063308 @default.
• W2487577029 hasConceptScore W2487577029C2778375690 @default.
• W2487577029 hasConceptScore W2487577029C2778850193 @default.
• W2487577029 hasConceptScore W2487577029C38180746 @default.
• W2487577029 hasConceptScore W2487577029C44249647 @default.

• next